Cross-Sector entity
Every one of those 1 sits in a single category, earnings. Of the tracked stories, 1 of 1 also mention Arcturus Therapeutics, the most common co-covered peer. The tracked stories average 2 original sources each. Blueprint Medicines appears in 1 tracked Cross-Sector story from March 2, 2026.
1 verified story tracked
Last mentioned: Mar 2, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, earnings. Of the tracked stories, 1 of 1 also mention Arcturus Therapeutics, the most common co-covered peer. The tracked stories average 2 original sources each. Blueprint Medicines appears in 1 tracked Cross-Sector story from March 2, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Blueprint Medicines. Shared-story counts are live from our verified record — not editorial picks.
Arcturus Therapeutics and Rigel Pharmaceuticals are preparing to report Q4 2025 results, highlighting a pivotal shift from clinical development to commercial execution. Investors are focused on Arcturus's mRNA vaccine rollout in Japan and Rigel's integration of its expanded oncology portfolio.
